Cardiovascular safety of liraglutide: Pooled analysis of Major adverse cardiovascular events across weight management and Type 2 Diabetes development programs

A meta-analysis of five phase II/III liraglutide (up to 3.0 mg) weight management (WM) trials, additional sensitivity meta-analyses of 21 liraglutide type 2 diabetes (T2D) trials (up to 1.8 mg) and a pre-specified pooled analysis of WM+T2D trials (n = 27) were performed to assess liraglutide's cardiovascular safety in individuals with overweight/obesity and T2D.